Collegium Pharmaceutical (COLL) Cost of Revenue (2016 - 2026)

Collegium Pharmaceutical has reported Cost of Revenue for 11 years, with the latest figure at $89.6 million in Q2 2026.

• On a quarterly basis, Cost of Revenue rose 12.52% year-over-year to $89.6 million in Q2 2026; TTM through Jun 2026 was $323.1 million, a 5.52% increase from a year earlier, with the FY2025 full-year figure at $3.1 million, down 98.8% from the prior year.
• Cost of Revenue was $89.6 million for Q2 2026 at Collegium Pharmaceutical, up from $76.3 million in the prior quarter.
• The five-year high for Cost of Revenue was $89.6 million in Q2 2026, with the low at $35.3 million in Q1 2022.
• Average Cost of Revenue over 5 years is $68.5 million, with a median of $69.7 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2023: Cost of Revenue surged 178.21% in 2022, then tumbled 30.96% in 2023.
• Over 5 years, Cost of Revenue stood at $79.8 million in 2022, then tumbled by 30.96% to $55.1 million in 2023, then soared by 51.79% to $83.7 million in 2024, then fell by 7.88% to $77.1 million in 2025, then grew by 16.24% to $89.6 million in 2026.
• The last three Cost of Revenue figures came in at $89.6 million (Q2 2026), $76.3 million (Q1 2026), and $77.1 million (Q4 2025), per Business Quant data.